Compare UXIN & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UXIN | IPSC |
|---|---|---|
| Founded | 2011 | 2019 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 275.0M | 268.0M |
| IPO Year | 2018 | 2021 |
| Metric | UXIN | IPSC |
|---|---|---|
| Price | $1.14 | $1.46 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.75 |
| AVG Volume (30 Days) | 421.9K | ★ 690.4K |
| Earning Date | 09-24-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $109,164,000.00 |
| Revenue This Year | $59.68 | N/A |
| Revenue Next Year | $71.25 | N/A |
| P/E Ratio | $4.05 | ★ N/A |
| Revenue Growth | N/A | ★ 1556.76 |
| 52 Week Low | $0.90 | $0.44 |
| 52 Week High | $4.18 | $2.97 |
| Indicator | UXIN | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 43.54 | 34.68 |
| Support Level | $1.07 | $0.90 |
| Resistance Level | $1.27 | $2.62 |
| Average True Range (ATR) | 0.12 | 0.12 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 17.07 | 31.43 |
Uxin Ltd is an investment holding company. Along with its subsidiaries, the firm operates a car retailer, pioneering industry transformation with production, new retail experiences, and digital empowerment in China. With its inventory-owning model, it provides customers a comprehensive transaction solution that encompasses the entire value chain, ranging from used-car acquisition, inspection, and reconditioning, warehousing, as well as pre-sales and after-sales services. The group offers high-quality and value-for-money used cars as well as superior full suites of services to customers through a reliable, one-stop, and hassle-free transaction experience. It derives revenues from retail vehicle sales, wholesale vehicle sales, and other businesses. The Group generates its revenues in China.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.